Pharmaceutical

BR-6002 by Boryung Pharmaceutical for Gastric Ulcers: Likelihood of Approval

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.

Aug 28, 2023 - 20:00
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
Read the original article

Tags:

Previous Article

BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: Likelihood of Approval

Next Article

BR-6002 by Boryung Pharmaceutical for Cardiovascular Disease: Likelihood of Appr...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The privileged status of orphan medicines in Germany

The privileged status of orphan medicines in Germany

Apr 27, 2024

FDA lifts clinical hold on PepGen’s myotonic dystrophy type 1 candidate

FDA lifts clinical hold on PepGen’s myotonic dystrophy ...

Oct 13, 2023

Signal: NHS whistle-blower policy questioned following Letby conviction

Signal: NHS whistle-blower policy questioned following ...

Aug 26, 2023